IMPACTO DO CANABIDIOL, SUPORTE DIETÉTICO PROTEICO E DERIVADOS DE TETRAHIDROCANABINOL NO PROGNÓSTICO DE PACIENTES COM IMUNOSSUPRESSÃO E CAQUEXIA ONCOLÓGICA GRAVE: UMA HIPÓTESE DE PLAUSIBILIDADE TERAPÊUTICA
DOI:
https://doi.org/10.58731/2965-0771.2025.58Resumen
A preservação da massa muscular é vital para a manutenção da vida. Principalmente no cenário oncológico, onde evidenciamos mudanças abruptas no comportamento alimentar. Essas alterações são justificadas inicialmente pelo dano emocional, ocasionado após o diagnóstico. Além dos efeitos colaterais comuns presentes no tratamento. Dentre eles, inapetência e enjoo, que são fatores determinantes para o sucesso na adesão. Per-se, a própria degradação muscular inflamatória ativada em ambiente tumoral, ou proveniente de imunossupressão oncológica, são fatores comprometedores, diretamente associados a prognóstico ruim e mortalidade acentuada. Aqui, nós abordamos hipoteticamente o potencial efeito terapêutico de aporte suplementar proteico ajustado, adicionado a derivados de CBD e THC, a fim de controlar o balanço nitrogenado proteico, reduzir a inflamação sistêmica e modular o humor em pacientes oncológicos.
Citas
1. Bauer J, Morley JE, Schols AMWJ, Ferrucci L, Cruz‐Jentoft AJ, Dent E, et al. Sarcopenia: a time for action. An SCWD position paper. Journal of cachexia, sarcopenia and muscle. 2019;10(5):956-61.
2. Prado CMM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. The lancet oncology. 2008;9(7):629-35.
3. Zhang Q, Song MM, Zhang X, Ding JS, Ruan GT, Zhang XW, et al. Association of systemic inflammation with survival in patients with cancer cachexia: results from a multicentre cohort study. J Cachexia Sarcopenia Muscle. 2021;12(6):1466-76.
4. Thibaut MM, Sboarina M, Roumain M, Pötgens SA, Neyrinck AM, Destrée F, et al. Inflammation‐induced cholestasis in cancer cachexia. Journal of cachexia, sarcopenia and muscle. 2021;12(1):70-90.
5. Baracos VE. Cancer-associated malnutrition. European journal of clinical nutrition. 2018;72(9):1255-9.
6. Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. Cancer-associated cachexia. Nature reviews Disease primers. 2018;4(1):1-18.
7. Britch SC, Babalonis S, Walsh SL. Cannabidiol: pharmacology and therapeutic targets. Psychopharmacology (Berl). 2021;238(1):9-28.
8. Hatfield J, Suthar K, Meyer TA, Wong L. The use of cannabinoids in palliating cancer-related symptoms: a narrative review. Proc (Bayl Univ Med Cent). 2024;37(2):288-94.
9. Grimison P, Mersiades A, Kirby A, Lintzeris N, Morton R, Haber P, et al. Oral THC: CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. Annals of Oncology. 2020;31(11):1553-60.
10. Peng J, Fan M, An C, Ni F, Huang W, Luo J. A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD). Basic & Clinical Pharmacology & Toxicology. 2022;130(4):439-56.
11. Russo EB. History of cannabis and its preparations in saga, science, and sobriquet. Chemistry & biodiversity. 2007;4(8):1614-48.
12. Gurgenci T, Kijanka G, Greer R, Huggett G, Good P, Moniruzzaman M, et al. Exploring potential anti-inflammatory effects of medicinal cannabis. Support Care Cancer. 2023;31(12):629.
13. Roxburgh CSD, McMillan DC. Cancer and systemic inflammation: treat the tumour and treat the host. British journal of cancer. 2014;110(6):1409-12.
14. Oliveira KG, von Zeidler SV, Lamas AZ, de Podestá JRV, Sena A, Souza ED, et al. Relationship of inflammatory markers and pain in patients with head and neck cancer prior to anticancer therapy. Brazilian Journal of Medical and Biological Research. 2014;47(7):600-4.
15. Bower JE, Ganz PA, Tao ML, Hu W, Belin TR, Sepah S, et al. Inflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer. Clinical Cancer Research. 2009;15(17):5534-40.
16. Wang XS, Shi Q, Shah ND, Heijnen CJ, Cohen EN, Reuben JM, et al. Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation. Clinical Cancer Research. 2014;20(5):1366-74.
17. Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clinical nutrition. 2008;27(6):793-9.
18. Abbass T, Dolan RD, Laird BJ, McMillan DC. The relationship between imaging-based body composition analysis and the systemic inflammatory response in patients with cancer: a systematic review. Cancers. 2019;11(9):1304.
19. Attaix D, Ventadour S, Codran A, Béchet D, Taillandier D, Combaret L. The ubiquitin–proteasome system and skeletal muscle wasting. Essays in biochemistry. 2005;41:173-86.
20. Sørensen J. Lung cancer cachexia: can molecular understanding guide clinical management? Integrative cancer therapies. 2018;17(3):1000-8.
21. Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, et al. ESPEN guidelines on nutrition in cancer patients. Clinical nutrition. 2017;36(1):11-48.
22. Kanarek N, Petrova B, Sabatini DM. Dietary modifications for enhanced cancer therapy. Nature. 2020;579(7800):507-17.
23. Velicer CM, Ulrich CM. Vitamin and mineral supplement use among US adults after cancer diagnosis: a systematic review. Journal of clinical oncology. 2008;26(4):665-73.
24. Cereda E, Turri A, Klersy C, Cappello S, Ferrari A, Filippi AR, et al. Whey protein isolate supplementation improves body composition, muscle strength, and treatment tolerance in malnourished advanced cancer patients undergoing chemotherapy. Cancer Medicine. 2019;8(16):6923-32.
25. Schuetz P, Fehr R, Baechli V, Geiser M, Deiss M, Gomes F, et al. Individualised nutritional support in medical inpatients at nutritional risk: a randomised clinical trial. The Lancet. 2019;393(10188):2312-21.
26. Roeland EJ, Bohlke K, Baracos VE, Bruera E, Del Fabbro E, Dixon S, et al. Management of cancer cachexia: ASCO guideline. Journal of Clinical Oncology. 2020;38(21):2438-53.
27. de van der Schueren MAE, Laviano A, Blanchard H, Jourdan M, Arends J, Baracos VE. Systematic review and meta-analysis of the evidence for oral nutritional intervention on nutritional and clinical outcomes during chemo (radio) therapy: current evidence and guidance for design of future trials. Annals of Oncology. 2018;29(5):1141-1153.
28. Prado CM, Anker SD, Coats AJS, Laviano A, von Haehling S. Nutrition in the spotlight in cachexia, sarcopenia and muscle: avoiding the wildfire. Journal of cachexia, sarcopenia and muscle. 2020;12(1):3.
29. Bargetzi L, Brack C, Herrmann J, Bargetzi A, Hersberger L, Bargetzi M, et al. Nutritional support during the hospital stay reduces mortality in patients with different types of cancers: secondary analysis of a prospective randomized trial. Annals of oncology. 2021;32(8):1025-33.
30. Tilch M-K, Galle P, Schattenberg J, Kostev K, Labenz C. Burden of depression and anxiety disorders per disease codes in patients with lymphoma in Germany. Supportive Care in Cancer. 2022;30.
31. Li X, Diviant JP, Stith SS, Brockelman F, Keeling K, Hall B, et al. The Effectiveness of Cannabis Flower for Immediate Relief from Symptoms of Depression. Yale J Biol Med. 2020;93(2):251-64.
32. Bloomfield MAP, Ashok AH, Volkow ND, Howes OD. The effects of Δ9-tetrahydrocannabinol on the dopamine system. Nature. 2016;539(7629):369-77.
33. Patel V, Borysenko M, Kumar MSA. Effect of Δ9-THC on brain and plasma catecholamine levels as measured by HPLC. Brain research bulletin. 1985;14(1):85-90.
34. Navari RM, Aapro M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. New England Journal of Medicine. 2016;374(14):1356-67.
35. Aapro M, Molassiotis A, Dicato M, Peláez I, Rodríguez-Lescure Á, Pastorelli D, et al. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Annals of oncology. 2012;23(8):1986-92.
36. Chow R, Valdez C, Chow N, Zhang D, Im J, Sodhi E, et al. Oral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting—a systematic review and meta-analysis. Supportive Care in Cancer. 2020;28:2095-103.
37. Grimison P, Mersiades A, Kirby A, Lintzeris N, Morton R, Haber P, et al. Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. Annals of Oncology. 2020;31(11):1553-60.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2025 Revista Brasileira de Cannabis
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
